www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

US EUROPE AFRICA ASIA 中文
Business / Companies

Pfizer bolsters China presence with $350m plant for biotech

(Agencies) Updated: 2016-06-29 09:57

Pfizer bolsters China presence with $350m plant for biotech

Headquarters of Pfizer Inc in New York. [Photo/China Daily]

Pfizer Inc said Tuesday it will invest $350 million in Hangzhou, eastern China on a plant for biotechnology drugs, bolstering its presence in the world's second biggest pharmaceutical market despite slowing economic growth in the country and rising pressure on prices for medicines.

The new facility is expected to be completed in 2018 and will manufacture biologics, or complex medicines made from living organisms, as well as biosimilars for patients in China and across the world, Pfizer said in an e-mail statement Tuesday.

Biosimilars are highly similar versions of biologic drugs that usually go through a complex manufacturing process. Making them requires greater precision than generics that copy relatively more straightforward chemical-based treatments.

The products from the plant will address major public health concerns such as oncology, the New York-based drugmaker said, without naming specific drugs. Biologics are underutilized in China, accounting for 4 percent of medicines prescribed in the country, compared with 22 percent in the US, according to the company.

A government-led campaign to reduce prices damped sales in China's pharmaceutical industry and the nation's economy has also slowed, leading to weaker sales growth in the country for drugmakers from Pfizer to the UK's GlaxoSmithKline Plc and AstraZeneca Plc last year. Still, multinationals, including Novartis AG, continue to invest in China, where a rising middle class is boosting spending on healthcare.

"China is one of the fastest growing pharmaceutical markets in the world and the ongoing China healthcare reform will continue to drive the expansion of China's pharmaceutical industry, including research and development," Pfizer said.

The new Pfizer facility will be its first biotechnology center in Asia and its third globally, the company said. Novartis unveiled a $1 billion campus in Shanghai this month, after Merck & Co opened a new research and development center on the outskirts of Beijing in April.

A slow approval process in China has delayed the entry of some cutting-edge new medicines by foreign drugmakers.

Hot Topics

Editor's Picks
...
主站蜘蛛池模板: 国产美女作爱 | 久久亚洲精品一区成人 | 久热精品免费视频 | 国产精品18久久久久久久久久 | 亚洲经典乱码在线播 | 国产91网 | 色偷偷亚洲男人天堂 | 97se亚洲综合在线 | 成人欧美网站 | 成人a毛片 | 成人18视频在线观看 | 91热视频在线观看 | 色爱综合网| 久久国产精品久久国产片 | 成人亚洲网站 | 久久精品中文字幕有码日本 | 久久免费视频播放 | 亚洲国产最新在线一区二区 | 波多野结衣福利视频 | 成人中文字幕在线观看 | 一级成人a做片免费 | 日本韩经典三级在线播放 | 九九九精品视频免费 | 亚洲国产日韩在线 | 欧美人在线 | 无限观看社区在线视频 | 成人免费手机在线看网站 | 亚洲欧洲日产国码二区在线 | 久草网首页 | 精品日韩二区三区精品视频 | 中文字幕波多野不卡一区 | 欧美一区二区三区精品影视 | 大伊香蕉精品视频在线观看 | 亚洲综合日本 | 成人在线播放视频 | 欧美日韩亚洲另类 | 国产裸体美女视频全黄 | 日本女人在线观看 | 国产aⅴ一区二区 | 99亚洲自拍 | 毛片免费在线观看网址 |